MX2020013068A - Anticuerpo anti proteína reguladora de señales alfa sirpalfana. - Google Patents
Anticuerpo anti proteína reguladora de señales alfa sirpalfana.Info
- Publication number
- MX2020013068A MX2020013068A MX2020013068A MX2020013068A MX2020013068A MX 2020013068 A MX2020013068 A MX 2020013068A MX 2020013068 A MX2020013068 A MX 2020013068A MX 2020013068 A MX2020013068 A MX 2020013068A MX 2020013068 A MX2020013068 A MX 2020013068A
- Authority
- MX
- Mexico
- Prior art keywords
- chain
- seq
- amino acid
- acid sequence
- sequence represented
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con el problema de proporcionar: un anticuerpo anti-SIRPa que puede usarse como agente tumoral; y un agente anti-tumoral que contiene el anticuerpo como ingrediente activo. La presente invención es un anticuerpo capaz de unir específicamente a SIRPa humana para inhibir la unión entre SIRPa humana y CD47, anticuerpo contiene: (a) una CDRL1 de cadena ligera que consiste en una secuencia de aminoácidos representada en la SEC. ID NO.: 1; (b) una CDRL2 de cadena ligera que consiste en una secuencia de aminoácidos representada por la SEC. ID NO.: 2; (c) una CDRL3 de cadena ligera que consiste en una secuencia de aminoácidos representada en la SEC. ID NO.: 3; (d) una CDRH1 de cadena pesada que consiste en una secuencia de aminoácidos representada en la SEC. ID NO.: 4; (e) una CDRH2 de cadena pesada que comprende una secuencia de aminoácidos representada en la SEC. ID NO.: 5; y (f) una CDRH3 de cadena pesada que comprende una secuencia de aminoácidos representada en la SEC. ID NO.: 6, en donde una región constante en cadena pesada es una región constante en cadena pesada de IgG4 humana y un residuo de fenilalanina en la posición 234, un residuo de leucina en la posición 235 y un residuo de serina en la posición 228, numerada de acuerdo con el índice EU como en Kabat et al., se sustituyen por un residuo de alanina, un residuo de alanina y un residuo de prolina, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018131116 | 2018-07-10 | ||
| PCT/JP2019/027114 WO2020013170A1 (ja) | 2018-07-10 | 2019-07-09 | 抗ＳＩＲＰα抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013068A true MX2020013068A (es) | 2021-03-02 |
Family
ID=69142391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013068A MX2020013068A (es) | 2018-07-10 | 2019-07-09 | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210155707A1 (es) |
| EP (1) | EP3822289A4 (es) |
| JP (2) | JP7368809B2 (es) |
| KR (1) | KR20210030267A (es) |
| CN (2) | CN117024593A (es) |
| AU (1) | AU2019302152A1 (es) |
| BR (1) | BR112020023322A2 (es) |
| CA (2) | CA3104462C (es) |
| CO (1) | CO2020014727A2 (es) |
| IL (1) | IL279321A (es) |
| MX (1) | MX2020013068A (es) |
| PH (1) | PH12021500002A1 (es) |
| SG (1) | SG11202012338QA (es) |
| TW (1) | TW202035449A (es) |
| WO (1) | WO2020013170A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2019183266A1 (en) | 2018-03-21 | 2019-09-26 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| JP2023509881A (ja) | 2019-12-24 | 2023-03-10 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| WO2022102634A1 (ja) | 2020-11-11 | 2022-05-19 | 第一三共株式会社 | 抗体－薬物コンジュゲートと抗ＳＩＲＰα抗体の組み合わせ |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN117425500A (zh) | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗dll3抗体-药物缀合物 |
| AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| BR112023025194A2 (pt) | 2021-06-04 | 2024-02-27 | Boehringer Ingelheim Int | Anticorpos anti-sirp-alfa |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4362977A1 (en) | 2021-06-29 | 2024-05-08 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202408584A (zh) * | 2022-05-10 | 2024-03-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與抗SIRPα抗體之組合 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| DE60334453D1 (de) * | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| PT1583830E (pt) | 2003-01-07 | 2006-11-30 | Symphogen As | Método para produzir proteínas policlonais recombinantes |
| US8613922B2 (en) * | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
| WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| AR068563A1 (es) * | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
| US8722587B2 (en) * | 2008-04-09 | 2014-05-13 | The Trustees Of The University Of Pennsylvania | Single chain fragment variable antibody libraries and uses thereof |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| TWI561531B (en) * | 2011-04-25 | 2016-12-11 | Daiichi Sankyo Co Ltd | Anti b7-h3 antibody |
| US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| MX2014011043A (es) * | 2012-03-13 | 2015-06-02 | Pioneer Hi Bred Int | Reduccion genetica de la fertilidad masculina en plantas. |
| EP2929032A4 (en) * | 2012-12-07 | 2016-04-06 | Solazyme Inc | GENETICALLY MODIFIED MICROBIAL STRAINS WITH CHLORELLA PROTOTHECOIDES LIPID SIGNAL PROGRAMS |
| PT3575326T (pt) | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
| WO2015138600A2 (en) * | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| US20180312600A1 (en) * | 2015-10-21 | 2018-11-01 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| US20190153095A1 (en) * | 2016-07-05 | 2019-05-23 | National University Corporation Kobe University | Antitumor Agent |
| CA3031034A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) * | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| JP2018131116A (ja) | 2017-02-17 | 2018-08-23 | いすゞ自動車株式会社 | ステップ取り付け構造 |
| CN110650976B (zh) | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
-
2019
- 2019-07-09 CN CN202311201098.2A patent/CN117024593A/zh active Pending
- 2019-07-09 AU AU2019302152A patent/AU2019302152A1/en active Pending
- 2019-07-09 KR KR1020207034952A patent/KR20210030267A/ko active Search and Examination
- 2019-07-09 SG SG11202012338QA patent/SG11202012338QA/en unknown
- 2019-07-09 CA CA3104462A patent/CA3104462C/en active Active
- 2019-07-09 WO PCT/JP2019/027114 patent/WO2020013170A1/ja unknown
- 2019-07-09 CN CN201980059246.7A patent/CN112673023B/zh active Active
- 2019-07-09 BR BR112020023322-6A patent/BR112020023322A2/pt unknown
- 2019-07-09 MX MX2020013068A patent/MX2020013068A/es unknown
- 2019-07-09 CA CA3219158A patent/CA3219158A1/en active Pending
- 2019-07-09 TW TW108124073A patent/TW202035449A/zh unknown
- 2019-07-09 JP JP2020530192A patent/JP7368809B2/ja active Active
- 2019-07-09 US US17/258,115 patent/US20210155707A1/en active Pending
- 2019-07-09 EP EP19833586.1A patent/EP3822289A4/en active Pending
-
2020
- 2020-11-27 CO CONC2020/0014727A patent/CO2020014727A2/es unknown
- 2020-12-09 IL IL279321A patent/IL279321A/en unknown
-
2021
- 2021-01-07 PH PH12021500002A patent/PH12021500002A1/en unknown
-
2023
- 2023-10-04 JP JP2023172481A patent/JP2023168526A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020023322A2 (pt) | 2021-02-02 |
| EP3822289A4 (en) | 2022-04-13 |
| CA3104462A1 (en) | 2020-01-16 |
| AU2019302152A1 (en) | 2021-01-07 |
| CO2020014727A2 (es) | 2020-12-21 |
| US20210155707A1 (en) | 2021-05-27 |
| CA3104462C (en) | 2023-12-19 |
| CN112673023A (zh) | 2021-04-16 |
| CN117024593A (zh) | 2023-11-10 |
| SG11202012338QA (en) | 2021-01-28 |
| JP2023168526A (ja) | 2023-11-24 |
| IL279321A (en) | 2021-01-31 |
| CA3219158A1 (en) | 2020-01-16 |
| KR20210030267A (ko) | 2021-03-17 |
| EP3822289A1 (en) | 2021-05-19 |
| WO2020013170A1 (ja) | 2020-01-16 |
| CN112673023B (zh) | 2023-09-12 |
| JP7368809B2 (ja) | 2023-10-25 |
| PH12021500002A1 (en) | 2021-09-13 |
| JPWO2020013170A1 (ja) | 2021-07-15 |
| TW202035449A (zh) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013068A (es) | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. | |
| PE20210628A1 (es) | Anticuerpos anti-cd73 y metodos de uso de los mismos | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| JP2017528476A5 (es) | ||
| NZ610153A (en) | Novel anti-dr5 antibody | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| AR068723A1 (es) | Proteina que se une a antigenos que se une a il-23 humana y sus usos | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| JP2018521638A5 (es) | ||
| IL259940B2 (en) | A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists | |
| RU2022108079A (ru) | Антитело против garp | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2013507991A5 (es) | ||
| RS52509B (en) | ANTI-IL-17 ANTITELA | |
| ZA202211246B (en) | Bispecific antibody | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso |